This type of lymphoma is most common in people from Asia and Central and South America. It is rare in people from other parts of the world, including the UK. It usually occurs in adults, at an average age of around 50. It affects more men than women.
There is a link between extranodal NK/T-cell lymphoma and infection with a virus called the Epstein-Barr virus (EBV), which also causes glandular fever.
Around 9 in 10 people in the general population have been infected with EBV by adulthood and the vast majority do not go on to develop lymphoma. It is not known why a few people who have EBV also develop extranodal NK/T-cell lymphoma.
Symptoms
Extranodal NK/T-cell lymphoma is usually found only in the area around the nose ('nasal') when it is diagnosed. This means it is most often at stage 1E or stage 2E, where 'E' stands for 'extranodal'. A few people have more widespread lymphoma (stage 3 or 4) when they are diagnosed.
A destructive mass most often forms inside the nose or in the sinuses (airfilled spaces) around the nose. Chemotherapy is given in cycles. The drugs are given on certain days, which are followed by a break in treatment for your body to recover before the next cycle begins.
If you are well enough, and your lymphoma has been reduced by chemotherapy, your doctor is likely to recommend you have more chemotherapy together with a stem cell transplant. This is to give you a better chance of staying in remission (no evidence of lymphoma) for a long time. ICE chemotherapy (ifosfamide, carboplatin and etoposide) is often used before a stem cell transplant, but your doctor might suggest a different regimen.
Relapsed or refractory extranodal NK/T-cell lymphoma
It is common for extranodal NK/T-cell lymphoma to relapse (come back) after being in remission. Sometimes the lymphoma is refractory (doesn't respond) to treatment. Should this be the case for you, your doctor might consider: a different chemotherapy regimen an allogeneic (donor) stem cell transplant if your lymphoma is reduced by chemotherapy and you are well enough a targeted drug, usually through a clinical trial.
Research and targeted treatments
There are several targeted drugs that can be effective in treating extranodal NK/T cell lymphoma, either on their own or together with chemotherapy.
These are usually only available if you are taking part in a clinical trial because they are still being investigated. You can find out more about clinical trials and search for a trial that might be suitable for you at Lymphoma TrialsLink.
Drugs being tested in extranodal NK/T cell lymphoma, but not yet approved in the UK, include: combined treatments that use antibodies to deliver chemotherapy to lymphoma cells, for example brentuximab vedotin (Adcetris®).
cell signal blockers that disrupt signals that keep cancer cells alive or allow them to grow. They act on different pathways in cells HDAC inhibitors like belinostat (Beleodaq®) or romidepsin (Istodax®), both of which are approved in the US for use in people with relapsed or refractory T-cell lymphoma PI3-K inhibitors like duvelisib PD1 or PD-L1 inhibitors like nivolumab and avelumab immunomodulatory drugs like lenalidomide (Revlimid®) and thalidomide. These affect the activity of the immune system in several different ways; they can help the immune system to attack the lymphoma cells and prevent the lymphoma from growing.
proteasome inhibitors like bortezomib (Bortezomib Accord or Velcade®) and carfilzomib. These disrupt the balance of proteins in cells, causing them to die.
New drugs are being developed and tested all the time. This is not intended to be a comprehensive list of drugs in development.
Follow-up
When your treatment is finished, you have regular follow-up appointments at the hospital. You are usually seen every 1-3 months at first, then every 6 months after a year or so. Your follow-up usually stops after around 3 years if you remain in remission. and would like to make a donation to support our work you can do so on our website www.lymphoma-action.org.uk/donate. Our information could not be produced without support from people like you. Thank you.
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